










NATIONAL CENTER FOR INFECTIOUS DISEASES (CVC) 

Plans, directs, and coordinates a national program to improve the identification, investigations, 
diagnosis, prevention, and control of infectious diseases.  In carrying out the mission, the Center: 
(1) provides leadership in investigation and diagnosis of infectious diseases of public health 
significance; (2) maintains surveillance of infectious diseases, disability, and death; (3) conducts 
applied and operational research related to definition, distribution, diagnosis, prevention, and 
control of infectious diseases, including vaccine development; (4) administers a biological 
reagents program which includes research on production, development of guidelines for 
production and utilization, and standardization, production, and distribution of reference 
reagents; (5) produces, evaluates, and distributes experimental vaccines, antisera and antitoxins, 
skin test antigens, and immune serum globulins to control and prevent laboratory infections and 
to prevent or minimize illness in certain population groups; (6) produces and distributes 
microbiological reference and working reagents not commercially available or of unreliable 
supply; (7) conducts applied research related to vectors of disease; (8) provides epidemic 
assistance; (9) maintains competence in the detection, identification, and control of rare, exotic, 
or tropical diseases; (10) provides reference diagnostic services; (11) provides technical 
assistance to states and localities and to other nations in the investigation, diagnosis, prevention, 
and control of infectious diseases; (12) provides scientific services in support of CDC=s 
laboratories; (13) provides epidemic aid to foreign nations and assists other nations in 
establishing and implementing infectious disease control programs; and (14) collaborates, as 
appropriate, with other Centers and Offices of the CDC in carrying out the above functions. 
(Approved 4/4/2002) 
Office of the Director (CVC1)
(1) Directs and manages the programs and activities of the National Center for Infectious 
Diseases (NCID); (2) provides leadership for the implementation of the Emerging Infections 
Plan to enhance the prevention and control of infectious diseases nationally and internationally; 
(3) provides leadership and guidance on policy, program planning and development, program
management, and operations; (4) provides NCID-wide administrative and program services, and 
coordinates or assures coordination with the appropriate CDC staff offices on administrative and 
program matters; (5) provides liaison with other Governmental agencies, international 
organizations, including the World Health Organization, and other outside groups;  
(6) coordinates, in collaboration with the appropriate NCID and CDC components, international 
health activities relating to the prevention and control of infectious diseases; (7) advises the 
Director, CDC, on policy matters concerning NCID programs and activities; (8) coordinates 
development and review of regulatory documents and congressional reports; (9) analyzes health 
programs and proposed legislation with respect to NCID=s programs, goals and objectives;  
(10) provides leadership and support for NCID Programs in the areas of statistics and database 
management.  (Approved 11/10/2003) 
Office of Administrative Services (CVC12)








NCID; (2) provides and coordinates NCID-wide administrative, management, and support 
services in the areas of fiscal management, personnel, travel, and other administrative services; 
(3) coordinates NCID requirements relating to procurement, materiel management, cooperative 
agreements, and reimbursable agreements; (4) provides leadership, guidance, and evaluation of 
administrative and management services performed at other geographic locations; (5) develops 
and implements administrative policies, procedures, and operations, as appropriate, for the 
NCID; and provides special reports and studies, as required, in the administrative management 
area; (6) maintains liaison with the Director, Office of Program Support, and Staff Service 
officials of the CDC. 
Office of Health Communication (CVC13)
(1) Provides national leadership, in consultation with the NCID divisions and programs and the 
CDC Office of Communication, on the implementation of a comprehensive and integrated 
program of public health communications for the prevention and control of new and reemerging 
infectious diseases; (2) plans, develops, coordinates, and evaluates NCID-wide networks, 
partnerships, systems, and standards for public and professional health communications;  
(3) advises the Director and other NCID leadership staff on health communication strategies;  
(4) provides expert technical assistance, consultation, and training to NCID staff on theory-based 
health education, behavioral science, distance education, community organization, and 
electronic, print, and oral communications; (5) develops infectious disease prevention and 
control messages and promotes their dissemination to lay and professional audiences through 
various marketing techniques; (6) investigates, plans, develops, evaluates, and promotes the use 
of electronic technology to expand NCID’s health communications capacity and impact in 
collaboration with CDC communication and information offices, state and local health 
departments, and other prevention partners; (7) provides services, coordination, identification, 
guidance, and training for, and promotes usage of, state-of-the-art electronic communication 
technologies; (8) provides clearance assistance in the preparation of scientific articles and other 
documents and products for electronic and hard copy publication or presentation; (9) produces 
NCID-wide publications, including a newsletter, anthologies and compilations, and cross-cutting 
background documents; and manages NCID=s technical information resources, including 
document databases.  (Approved 7/21/2006) 
Office of Surveillance (CVC14)
(1) Provides leadership, guidance, and coordination on NCID surveillance activities and systems; 
(2) provides NCID leadership on issues related to internal and external integration of CDC 
surveillance; (3) advises the Director on surveillance priorities for determining the burden of 
infectious diseases; (4) provides direction and oversight for the Emerging Infections Programs 
(EIPs) and sentinel surveillance networks through cooperative agreements with state/local health 
departments and other organizations; (5) provides technical assistance and direction for 
surveillance activities in the Epidemiology and Laboratory capacity cooperative agreements and 
other emerging infections activities/programs with a surveillance emphasis; (6) provides 
leadership for enhancing surveillance of infectious diseases through collaboration with managed 
care organizations; (7) provides technical leadership for and consultation on international 















and prevention effectiveness evaluation of infectious disease control and prevention activities; 
(9) in carrying out the above functions, collaborates, as appropriate, with other Centers, Institute, 
and Offices (CIOs) of the CDC. (Approved 6/1/1998) 
Division of Global Migration and Quarantine (CVCB)
(1) Administers a national quarantine program to protect the United States against the
introduction of diseases from foreign countries and the transmission of communicable disease 
between states; (2) administers an overseas program for the medical examination of immigrants, 
refugees, and as necessary other migrant populations destined for legal entry to the U.S., with 
inadmissible health conditions that would pose a threat to public health and impose a burden on 
public health and hospital facilities; (3) conducts surveillance, research, and prevention programs 
to prevent minimize morbidity and mortality among the globally mobile populations entering and 
leaving the United States; (4) maintains liaison with and provides information on global 
migration and quarantine matters to other Federal agencies, state and local health departments, 
and other stake holders; (5) provides liaison with international health organizations, such as the 
Pan American Health Organization and the World Health Organization, and participates in the 
development of international agreements affecting quarantine; (6) evaluates and provides 
technical support on the development and enforcement of policies necessary for implementation 
of federal quarantine authority; (7) conducts studies to provide new information about health 
hazards abroad, measures for their prevention, and the potential threat of disease introduction 
into the United States; and (8) provides logistic support to other programs of the Centers for 
Disease Control and Prevention in the distribution of requested biologicals agents and movement 
of biological specimens through U.S. ports of entry.  (Approved 10/19/2004) 
Office of the Director (CVCB1)
(1) Manages, directs, and coordinates the activities of the Division; (2) provides leadership in 
development of Division policy, program planning, implementation, and evaluation;  
(3) identifies needs and resources for new initiatives and assigns responsibilities for their 
development; (4) coordinates liaison with other Federal agencies, State and local health 
departments, and interested industries; (5) coordinates liaison with international health 
organizations; (6) provides administrative services, including procurement, property and supply 
management, travel arrangements, space and facilities maintenance, and timekeeper 
coordination; (7) provides personnel support to the Division, both for Civil Service and 
Commissioned Corps employees, and assures compliance with HRMO regulations for all 
personnel matters; and (8) reviews and evaluates all administrative services for both headquarters 
and Quarantine Stations and provides policy procedures and guidance on such matters. 
(Approved 10/19/2004) 
Quarantine and Border Health Services Branch (CVCBB)
(1) Develops and implements strategies to monitor for diseases of public health interest arriving 
persons, animals, cargo, and conveyances at ports of entry to the United States and its 
possessions; (2) evaluates and revises public health preparedness activities at airports, seaports, 






effective application of scientific data in implementing programs to monitor the importation of
quarantinable and other specified diseases; (4) develops and initiates surveillance and other 
public health activities at sea, air, and land ports of entry to the United States and its possessions; 
(5) trains and supervises field staff in the epidemiologica, technical, management, and 
administrative aspects of quarantine operations; (6) works cooperatively with other agencies and 
organizations in the United States and abroad to implement, improve, and enhance division 
activities at ports of entry to the United States and its possessions; (7) provides technical 
consultation and public health training to federal inspection services to implement the division’s 
activities, apply CDC regulations on quarantine, and ensure appropriate occupational safety and 
health protection for their staff; (8) collaborates with State and local health departments to 
prevent transmission and spread of quarantinable diseases and other diseases of public health 
significance associated with travel; (9) monitors arriving immigrants and refugees at ports of 
entry to the United States and its possessions and notifies State health departments on identified 
health conditions; (10) provides logistic support to other CDC programs and expedites the 
movement of persons, clinical specimens, lifesaving medications, and other materials through 
federal security; (11) serves as CDC’s representative at U.S. ports of entry for operational issues 
related to bio security and emerging infections; and 12) administers Deratting Certification 
program.  (Approved 10/19/2004) 
Immigrant Refugee and Migrant Health Branch (CVCBC)
(1) Develops and maintains surveillance systems for infectious diseases among immigrant, 
refugee, and migrant populations entering the United States or designated for resettlement in the 
United States; (2) conducts infectious disease surveillance and epidemiological investigations in 
communities along the U.S.-Mexico border; (3) recommends appropriate, effective intervention 
and prevention strategies to decrease morbidity and  mortality among globally mobile 
populations and to prevent entry of disease into the United States; (4) performs epidemiologic 
investigations and scientific research projects related to health issues for immigrant, refugee, and 
migrant populations; (5) develops, reviews, and evaluates operations in the United States and 
abroad involving immigrant and refugee medical examination activities; (6) conducts enhanced 
refugee medical screening examinations; (7) responds to refugee resettlement emergencies, 
including the provision of technical assistance regarding clinical management and effective 
interventions to prevent and control infectious diseases in this setting; 8) conducts a continuing 
review of medical screening procedures to assure the most effective application of current 
medical practices; administers and monitors activities related to the overseas and domestic 
medical examinations of immigrants and refugees, convening boards of medical officers to 
reexamine immigrants and refugees, when necessary, and preparing, publishing, and distributing 
manuals for examining physicians; (9) works cooperatively and in concert with other Federal and 
international agencies, voluntary agencies, and foreign governments, both in the United States 
and abroad, in administering the immigrant and refugee medical screening program;  
(10) establishes, maintains, and evaluates medical inspection and notification procedures 
regarding immigrants and refugees, providing coordination and liaison with local and state health 
departments on the follow-up of those with serious disease or mental problems, in particular 
notifiable diseases such as tuberculosis; (11) establishes and maintains procedures to process 
requests for waivers of inadmissible medical conditions; (12) provides scientific and technical 








(13) provides liaison and coordination of efforts with counterparts in other divisions and centers 
of CDC, as well as national and international agencies involved in addressing and preventing 
infectious diseases among globally mobile populations. (Approved 10/19/2004) 
Geographic Medicine and Health Promotion Branch (CVCBD)
 (1) Through the GeoSentinel Network develops geographic-specific infectious disease risk 
profiles among mobile populations; (2) coordinates and provides immunization data and 
recommends appropriate and effective intervention and prevention strategies to decrease 
morbidity and mortality among  international travelers; (3) develops and issues vaccination 
documents and validation stamps in accordance with the International Health Regulations;  
(4) conducts surveillance for and assists in investigations of adverse events following 
administration of traveler vaccines; (5) alerts appropriate disease-specific CDC programs about 
possible imported cases if disease and supports the relevant program to investigate these events; 
(6) monitors and analyzes reports of health threats overseas and issues travel notices, alerts and 
advisories when appropriate; (7) notifies the World Health Organization of the incidence of 
quarantinable diseases in the United States, as required by the International Health Regulations; 
(8) inspects shipments of nonhuman primates to ensure compliance with CDC regulations 
regarding quarantine, conditions of shipment and occupational safety and health of employees 
exposed to primates; (9) works to decrease the risk of importing zoonotic diseases of public 
health significance to humans via animals and cargo; (10) performs epidemiologic investigations 
and scientific research projects among U.S. travelers and imported animals; (11) periodically 
conducts active surveillance for infectious diseases among imported animals; (12) provides 
scientific and technical support to the operation and regulatory responsibilities of the Division; 
and (13) provides liaison and coordination of efforts with counterparts in other divisions of CDC, 
state and local health authorities, the travel industry, as well as national and international 
agencies involved in addressing and preventing infectious diseases among international travelers 
and translocated animals. (Approved  10/19/2004) 
Arctic Investigations Program (CVCC)
(1) Conducts surveillance of infectious diseases and conditions that impact the health of all 
residents of the circumpolar region with special emphasis on diseases of high incidence and 
concern among indigenous peoples of these regions; (2) designs and conducts epidemiologic 
studies to investigate the causes and risk factors for infectious diseases among residents of the 
Arctic and sub-Arctic, and conducts long-term studies to determine sequelae of various etiologic 
agents; (3) conducts laboratory research to evaluate existing laboratory tests, modifies methods 
as needed to apply the technology in the Arctic health-care setting, and develops new methods 
for diagnosis, treatment, and follow-up of health problems; (4) designs and implements studies to 
evaluate strategies for control of infectious diseases among residents and travelers in the Arctic 
in collaboration with, the State of Alaska, foreign ministries of health, universities, National 
Institutes of Health, organizations in Alaska, and other programs within CDC; (5) provides 
epidemiologic, statistical, computer, and laboratory consultation to organizations in Alaska, other 
health providers, and public and private health agencies; (6) assists local, national, and 
international agencies and organizations in developing guidelines for infectious disease 













of particular import for residents of circumpolar regions; (8) provides training and technological 
assistance in epidemiology, statistics, and laboratory methodology to health-care personnel 
working or planning to conduct research in the Arctic; (9) participates in the Arctic Council 
proceedings, the International Union for Circumpolar activities and other international 
collaborative efforts to improve the health of all circumpolar populations; and (10) as the 
predominate Federal agency conducting infectious diseases research in the Arctic, provides local 
input as needed to the Office of the Director CDC, the Interagency Arctic Research and Policy 
Committee, Arctic Research Commission, and National Science Foundation as established under 
the U.S. Arctic Research and Policy Act of 1984.  (Approved 7/13/2001) 
Office of the Director (CVCC1)
(1) Manages, prioritizes, directs, and coordinates the activities of the Arctic Investigation 
Program (AIP); (2) provides leadership and guidance on policy, program planning and 
development, program management, and operations; (3) provides AIP-wide administrative 
services, and coordinates or assures coordination with the appropriate NCID and CDC staff 
offices on administrative and program matters; (4) provides liaison with other Governmental 
agencies, international organizations, and other outside groups; (5) advises and represents the 
Director, NCID on policy matters concerning American Indians and Alaska Natives and on 
Arctic health issues in general; (6) responsible for budget formulation; (7) responsible for facility 
management, security, and employee safety; (8) responsible for the editing, clearance, and 
tracking of manuscripts for publication, abstracts for presentation, and protocols for Institutional
Review Board (IRB) and human subjects review; (9) provides technical aid, consultation, and 
training to AIP staff on health education, behavioral science, distance education, community 
organization, and electronic, print, and oral communications; and sponsors and participates in 
national and international meetings and conferences. (Approved 9/29/2004) 
Division of Healthcare Quality Promotion (CVCD)
Protects patients, protects healthcare personnel, and promotes safety, quality, and value in the 
healthcare delivery system by providing national leadership for (1) measuring, validating, 
interpreting, and responding to data relevant to healthcare outcomes, healthcare-associated 
infections/antimicrobial resistance,  related adverse events, and medical errors among patients 
and healthcare personnel; (2) investigating and responding to outbreaks and emerging infections 
and related adverse events among patients, healthcare providers, or associated with the 
healthcare environment; (3) detecting, evaluating, monitoring, and responding to emerging 
antimicrobial resistant pathogens and infections; (4) creating and evaluating the efficacy of new 
interventions designed to prevent infections/antimicrobial resistance, related adverse events, and 
medical errors; (5) promoting clinical microbiology laboratory quality; (6) promoting water 
quality in healthcare settings; (7) identifying effective interventions that prevent healthcare-
associated infections/antimicrobial resistance, related adverse events, and medical errors among 
patients and healthcare personnel; (8) promoting the nationwide implementation of these 
interventions; and (9) evaluating the impact of their implementation across the spectrum of 
healthcare delivery sites. (Approved 1/30/2001) 









(1) Manages, directs, and coordinates the activities of the Division of Healthcare Quality 
Promotion (DHQP); (2) provides leadership and guidance on policy, program planning and 
development, program management, and operations; (3) provides DHQP-wide administrative 
and program services and coordinates or ensures coordination with the appropriate National 
Center for Infectious Diseases (NCID) and Centers for Disease Control and Prevention (CDC) 
staff offices on administrative and program matters; (4) provides liaison with other governmental 
agencies, international organizations, and other outside groups; (5) coordinates, in collaboration 
with the appropriate NCID and CDC components, global health activities relating to the 
prevention of healthcare-associated infections/antimicrobial resistance, related adverse events, 
and medical errors; (6) manages the division local area network (LAN) and coordinates the 
evolving LAN design with the Information Resources Management Office and the NCID LAN 
administrator; (7) provides hardware and software support to DHQP personnel in  response to the 
changing information technology environment; and (8) advises the Director, NCID, on policy 
matters concerning DHQP activities.  (Approved 1/30/2001) 
Epidemiology and Laboratory Branch (CVCDB)
(1) Coordinates rapid and effective epidemiologic and laboratory response to outbreaks and 
emerging threats associated with infections/antimicrobial resistance and related adverse events 
throughout the healthcare delivery system; (2) provides comprehensive laboratory support and 
expertise (including consultation; organism recovery and identification; microbiologic, toxin, 
chemical, and molecular assays; and strain typing) for investigations of recognized and emerging 
bacterial agents (including those resistant to available antimicrobials) in healthcare settings;  
(3) implements surveillance and response systems to detect emerging threats, including those  
related to agents of bioterrorism, among patients and healthcare personnel; (4) investigates novel 
and emerging mechanisms of antimicrobial resistance among targeted pathogens found in 
healthcare settings; (5) conducts epidemiologic and basic and applied laboratory research to 
identify new strategies to prevent infections/antimicrobial resistance, related adverse events, and 
medical errors, especially those associated with indwelling medical devices, contaminated 
products, dialysis, and water; (6) evaluates the accuracy of commercial microbial identification 
and susceptibility testing systems and products through research and facilitates their 
improvement; (7) provides leadership in reducing microbiology laboratory errors that affect 
patient outcomes  by evaluating laboratory proficiency and promoting laboratory quality 
improvements; (8) investigates the role of biofilms, particularly those detected in indwelling 
medical devices and medical water systems, in medicine and public health; and (9) in 
collaboration with other CDC Centers, Institutes, and Offices (CIOs) and partners, provides 
expertise (e.g. environmental sampling, microbial assays, environmental engineering, 
disinfection strategies), research opportunities, and laboratory support for investigations of 
environmental sources of infections and related adverse events, including those related to 
bioterrorism. (Approved 1/30/2001) 
Prevention and Evaluation Branch (CVCDC)
(1) Supports local, state, national, and international efforts to prevent healthcare-associated 






   
 
based recommendations and state-of-the art informatics and health communications strategies 
that enhance rapid and reliable information exchange; (2) develops and demonstrates the 
effectiveness of health communications, guidelines, recommendations, and other interventions to 
prevent healthcare-associated infections/antimicrobial resistance, related adverse events, and 
medical errors across the spectrum of healthcare delivery sites; (3) promotes the implementation 
of effective guidelines, recommendations, and other interventions to prevent healthcare-
associated infections/antimicrobial resistance, related adverse events, and medical errors;  
(4) evaluates the impact of implementation of effective guidelines, recommendations, and other 
interventions on healthcare-associated infections/antimicrobial resistance, related adverse events, 
and medical errors; (5) provides consultation, guidance, and technical support to domestic and 
international partners on the prevention of healthcare-associated infections/antimicrobial 
resistance, related adverse events, and medical errors; and (6) develops and disseminates training 
tools and other strategies that enhance local capacity to protect patients and healthcare personnel 
and to promote quality healthcare.  (Approved 1/30/2001) 
Healthcare Outcomes Branch (CVCDD)
(1) Evaluates the impact of healthcare-associated infections/antimicrobial resistance, related 
adverse events, and medical errors on healthcare outcomes and costs in order to establish 
priorities for DHQP intervention programs; (2) improves methods to measure healthcare 
outcomes, performance, and cost-effectiveness of intervention strategies; (3) improves systems 
by which healthcare organizations collect, manage, analyze, report, and respond to data on 
healthcare outcomes, healthcare-associated adverse events, and medical errors; (4) implements 
and coordinates the National Healthcare Safety Network (NHSN) (a representative sample of 
healthcare organizations that report data on targeted  healthcare-associated adverse events and 
medical errors) to obtain locally relevant and scientifically valid benchmarks and performance 
measurements that promote healthcare quality and value; (5) provides national estimates of 
targeted adverse events and medical errors among selected populations of patients across the 
spectrum of healthcare delivery sites; and (6) provides national estimates of targeted 
occupational illnesses and injuries among healthcare workers across the spectrum of healthcare 
delivery sites. (Approved 1/30/2001) 
Scientific Resources Program (CVCE)
(1) Provides animals, animal and human blood products, glassware, mammalian tissue cultures, 
microbiological media, special reagents, and other laboratory materials in support of research 
and service activities to NCID laboratories and other CDC organizations; (2) installs, fabricates, 
modifies, services, and maintains laboratory equipment used in the research and service activities 
of CDC; (3) develops and implements applied research programs to expand and enhance the use 
of animal models necessary to support research and diagnostic programs and to improve 
breeding and husbandry procedures; (4) conducts both basic and applied research in cell biology 
and in the expansion of tissue culture technology as a research and diagnostic tool for infectious 
disease activities; (5) provides services for NCID investigators in protein and DNA synthesis 
and sequencing; (6) maintains a bank of serum and other biological specimens of 
epidemiological and special significance to CDC's research and diagnostic activities; (7) obtains 









globulins; (8) manages and distributes the inventory, maintains the computerized system
database, and provides general technical service support for dispensing, lyophilizing, capping, 
and labeling CDC Reference Reagents; (9) provides support for liquid nitrogen freezers;  
(10) provides computer support services for the Program's activities; (11) receives, categorizes, 
processes and distributes specimens to CDC laboratories for reference diagnostic testing, 
research studies, and epidemics and reports diagnostic test results to submitting organizations; 
(12) manages all CDC exports and ensures compliance with regulations and serves as CDC 
liaison with Department of Commerce for export related issues; (13) maintains the CDC Atlanta 
laboratory water treatment systems; (14) provides collaborative development and production 
services to produce high priority reference reagents and specialized diagnostics for internal 
NCID investigators. (Approved 6/22/2006) 
Animal Resources Branch (CVCEB)
(1) Acquires and distributes laboratory animals for research; (2) provides veterinary services and 
animal husbandry for experimental animals, and collaborates on research using laboratory 
animals; (3) ensures the standardization of animal husbandry procedures in the Atlanta Area 
CDC Animal Facilities; (4) develops standard operating procedures for animal care and use in 
accordance with policies established by the CDC Animal Policy Board and those endorsed by the 
American Association for Accreditation of Laboratory Animal Care; (5) conducts applied 
research to improve the care and use of animals for research and testing; (6) provides veterinary 
care, including clinical and surgical support for the care and use of laboratory animals;  
(7) conducts laboratory animal technology training for investigators, technicians, and animal care 
personnel. (Approved 10/22/1999) 
Biologics Branch (CVCEC)
(1) Establishes and practices quality control and assurance procedures to ensure high product 
quality and integrity and compliance with changing FDA regulations and GMP standards;  
(2) provides consultation and training to CDC laboratorians and extramural organizations on cell 
culture techniques, media production methods and related procedures; (3) conducts applied and 
basic research, independently and collaboratively, on problems related to mammalian cell 
cultures, cell biology, expression systems, specialized diagnostics, microbiologic fermentation, 
and hybridomas; (4) develops, produces, evaluates, or procures and distributes mammalian 
primary cell cultures, cell lines, hybridomas, cell culture and microbiological media, chemical 
reagents, animal blood products and in vitro diagnostic products to CDC scientists for diagnostic 
and research purposes; (5) manages a bank of cell line cultures for use in diagnostic and research 
activities; (6) in coordination with NCID/OD, determines the need and priorities for development 
of infectious pathogen reference diagnostic reagents and collaborates with CDC laboratory 
personnel in developing new and improved hybridomas and reference diagnostic reagents;  
(7) manages the CDC Reference Reagent Inventory, processes requisitions, distributes, and 
provides information to CDC and non-CDC laboratorians on infectious pathogen reference 
reagents; (8) provides dispensing, lyophilizing, capping, and labeling services for products 
prepared at CDC; (9) provides and maintains a fermentation facility for routine service 
fermentations and research projects; (10) maintains a computer system for ordering products and 















Biotechnology Core Facility Branch (CVCED)
(1) Provides to NCID components the instrumentation and expertise required to develop, refine, 
and apply modern technologies pertinent to the prevention and control of infectious, 
autoimmune, neoplastic, and hematologic diseases; (2) provides synthetic oligonucleotides 
useful in the analysis of the genetics of pathogens and in the development of rapid diagnostic 
tests; (3) develops methodologies for automated DNA sequence analysis and assists in their 
application; (4) determines the physicochemical properties and the primary amino acid sequence 
of proteins of biological interest; (5) provides synthetic peptides to facilitate studies of
antigen/antibody interactions and to aid in the formulation of synthetic vaccines; (6) participates 
as a reference laboratory in standardizing methods and materials for protein chemistry;  
(7) acquires and maintains computer software for the analysis of biological macromolecules, and 
assists other NCID researchers in its use. 
Specimen Management Branch (CVCEE)
(1) Stores serum collections and other biological specimens that relate to ongoing and approved 
epidemiologic, surveillance, and special project studies; (2) receives, processes, catalogs, stores, 
and distributes biological specimens and associated information to qualified investigators upon 
request; (3) receives, processes, stores, and distributes AIDS and AIDS related 
plasma/serum/mononuclear cell specimens;  (4) provides controlled rate freezing for cells and 
tissues; (5) procures, processes, and distributes human blood and blood products; (6) maintains a 
comprehensive inventory and tracking system of inventoried specimen collections;   
(7) coordinates technical data and specimen handling services for laboratory activities of CDC 
programs;  (8) provides consultation and training in technical services;  (9) receives and ships 
infectious substances and other material for CDC laboratories. (Approved 10/25/1999)  
Laboratory Support Branch (CVCEG)
(1) Coordinates technical services for laboratory activities of CDC programs including 
procurement, processing, and distribution of glassware and related items, laboratory waste 
decontamination and disposal, laundry services, laboratory equipment management and 
maintenance, and materiel management; (2) provides consultation and training in technical 
services; and (3) maintains laboratory water treatment systems to ensure quality of CDC reagent 
laboratory water.  (Approved 10/25/1999) 
Division of Bacterial and Mycotic Diseases (CVCG)
(1) Conducts surveillance, investigations, and studies of bacterial, fungal, and actinomycotic 
diseases to define disease etiology and develop effective methods for diagnosis, prevention, and 
control; (2) conducts or participates in clinical, field, and laboratory research to develop, 
evaluate, and improve laboratory methodologies and materials and therapeutic practices used for 
diagnosis, treatment, investigation, and control of bacterial, fungal, and actinomycotic diseases; 
(3) conducts research on development and evaluation of immunizing agents and the role of 











consultation, upon request, to State and local health departments, other Federal agencies, and 
national and international health organizations; (5) provides reference/diagnostic services for 
bacterial, fungal, and actinomycotic diseases to State and local health departments, other Federal 
agencies, and national and international health organizations; (6) provides scientific and 
technical assistance to other NCID components when the work requires unique expertise or 
specialized equipment not available in other components; (7) provides intramural and extramural 
technical expertise and assistance in professional training and proficiency testing activities; 
(8) serves as appropriately designated national and international reference centers for various 
bacterial, fungal, and actinomycotic diseases and disease groups. 
Biostatistics and Information Management Branch (CVCGB)
(1) Provides statistical methodology and participates in the Division's epidemic investigations, 
surveillance systems for ongoing surveillance; (2) designs disease reporting systems for ongoing 
surveillance; (3) provides statistical consultation for Division personnel, other CDC officials, 
public health officials and other scientific researchers outside the CDC; (4) develops methods or 
adapts existing methods for laboratory research studies; (5) coordinates Division information 
management with NCID, IRMO, and other CDC organizations; (6) provides statistical training 
for professional staff of the Division; (7) sets Division policy on statistical procedures, analysis 
of surveillance data, and procedures for data collection and processing.  (Approved 11/10/2003) 
Respiratory Diseases Branch (CVCGC)
(1) Conducts epidemiologic and laboratory studies to monitor burden of diseases (e.g. 
survillance), provides assistance in control of epidemics and exploits opportunities to improve 
control and prevention of respiratory and other syndromes caused by Streptococcus pneumoniae, 
group A and B streptococci, atypical respiratory bacteria (Legionella, Mycoplasma, and 
Chlamydia species), and Haemophilus influenzae in resource poor areas; as well as community-
acquired drug resistant bacterial infections, community-acquired pneumonia and neonatal sepis; 
(2) coordinates divisional activities related to Active Bacterial Core surveillance (ABCs) with the 
Emerging Infections Program states; (3) facilitates development and evaluation of immunizing 
agents for prevention and characterization of the immune response to pathogens listed above as 
well as for Neisseria meningitidis; (4) provides reference and diagnostic activities for respiratory 
bacterial diseases and for the identification of unknown gram positive cocci; (5) develops, 
implements and evaluates prevention strategies for these diseases as well as promotion of 
appropriate antimicrobial use and control of antimicrobial resistant respiratory infections;  
(6) maintains WHO collaborating centers for Streptococci and for Research and Reagents for 
Human selected human bacterial diseases; (8) collaborates with other CDC C/I/O, NCID 
divisions, state and federal agencies, WHO, PAHO, private industry and academia, and other 
governmental organizations involved in public health.  (Approved 12/7/2003) 
Mycotic Diseases Branch (CVCGD)
(1) In collaboration with other CDC C/I/Os and other NCID divisions, conducts laboratory 
studies and provides epidemic aid, surveillance, and consultation on the control of emerging, 











for agents causing these diseases and for the identification of unknown mycotic isolates 
associated with human disease; (3) performs studies to determine host-parasite factors related to 
human diseases caused by emerging, reemerging, and opportunistic mycotic agents;  
(4) coordinates and collaborates in national and international studies and surveillance for mycotic 
diseases; (5) develops and evaluates methods for the diagnosis of emerging, reemerging, and 
opportunistic mycotic diseases; (6) develops, implements, and evaluates prevention strategies for 
these diseases; (7) collaborates with other CDC Centers/Institutes/Offices, NCID divisions, state 
and Federal agencies in addressing reemerging mycotic diseases. 
Meningitis and Special Pathogens Branch (CVCGE)
(1) Conducts epidemiologic and laboratory studies to monitor burden of diseases (e.g. 
surveillance), provides assistance in control of epidemics and exploits opportunities to improve 
control and prevention of bacterial illness including: meningitis, zoonoses, (leptospirosis, 
brucellosis and anthrax), mycobacterium infections other than tuberculosis, toxic shock syndrom, 
Brazilian purpuric fever and unexplained deaths and serious illnesses; (2) provides laboratory 
support for diphtheria and pertussis; (3) provides reference and diagnostic activities for agents 
causing these diseases and for the identification of unknown bacterial isolates associated with 
human diseases; (4) participates in the development and evaluation of vaccines for these 
diseases; (5) develops, implements and evaluates prevention strategies for these diseases;  
(6) maintains WHO collaborating centers for: control and prevention of epidemic meningitis and 
epidemiology of leptospirosis; (7) collaborates with other CDC C/I/O, NCID division, state and 
Federal agencies, Ministers of Health, WHO, PAHO, private industry and other governmental 
organizations involved in public health.  (Approved 12/7/2003) 
Foodborne and Diarrheal Diseases Branch (CVCGG)
(1) Conducts laboratory studies and provides epidemic aid, surveillance, consultation on the 
control of foodborne and waterborne outbreaks of acute gastrointestinal illness; (2) provides 
reference and disease surveillance activities for agents of selected foodborne, waterborne, and 
other bacterial enteric diseases; (3) performs studies to determine host-parasite factors related to 
foodborne, waterborne, and other bacterial enteric diseases; (4) coordinates and collaborates in 
national and international enteric disease studies, including foodborne diseases; (5) coordinates 
program activities regarding minority health issues within the Division and with appropriate 
organizations outside the Division; (6) coordinates travel health issues with the Division of 
Quarantine in the National Center for Prevention Services; (7) develops, implements, and 
evaluates prevention strategies for bacterial enteric diseases affecting persons in resource-poor 
settings; (8) develops and implements prevention strategies for foodborne and waterborne 
diseases in consultation with food safety regulatory agencies and the food industry. (Approved  
04/16/1993) 
Division of Parasitic Diseases (CVCH)
(1) Conducts surveillance, investigations, and studies of parasitic diseases to define disease 
etiology, mode of transmission, and populations at risk and to develop effective methods for 








laboratory research to develop, evaluate, and improve laboratory methodologies and materials 
and therapeutic practices used for rapid and accurate diagnosis and treatment of parasitic 
diseases (3) provides epidemic aid and epidemiologic consultation, upon request, to State and 
local health departments, other Federal agencies, and national and international health 
organizations; ( 4) provides reference/diagnostic services for parasitic diseases to State and local 
health departments, other Federal agencies, and national and international health organizations; 
(5) conducts a program of research and development in the biology, ecology, host-parasitic 
relationships, and control of parasitic diseases; (6) conducts laboratory studies of selected 
parasitic infections, emphasizing animal models and in vitro systems for parasitic relationships, 
chemotherapy, and immunology, to develop effective methods for diagnosis, prevention, and 
control; (7) provides scientific and technical assistance to other components within NCID or 
CDC when the work requires unique expertise or specialized equipment not available in other 
NCID or CDC components;  (8) provides intramural and extramural technical expertise and 
assistance in professional training; (9) serves as World Health Organization (WHO) 
Collaborating Centers for for Cysticercosis, Research Training and Control of Dracunculiasis, 
Control and Elimination of Lymphatic Filariasis, Evaluating and Testing New Insecticides, 
Insecticide Resistance, Insect Vectors; Malaria Control in Africa, Human African 
Trypanosomiasis, Production and Distribution of Malaria Sporozoite ELISAs, Collaborating 
Centers for Eradication of Guinea Worm; (10) maintains field-based research stations in 
Guatemala in collaboration with Universidad del Valle de Guatemala, and in Kenya in 
collaboration with KEMRI;  (11) carries out this mission is a workplace that promotes 
professional development and recognizes the importance of the individual and the team; and,  
(12) provides communication support to enhance overall methods of dissemination of credible 
information to the public, local and state health officials, international partners and private 
funders in order to inform health decisions to prevent and control parasitic diseases in the United 
States and abroad. The services are provided through the partnerships with health care 
professionals, state, local and federal agencies with the United States, foreign governments, 
national and international organizations, and the public. (Approved 7/27/2004) 
Data Management Activity (CVCH12)
(1) Provides statistical and information systems consultation for study design and protocol 
development; (2) designs and implements database management systems (including geographic 
information systems) in support of the Division of Parasitic Diseases (DPD) projects;  
(3) provides data analysis and statistical consultations in support of DPD projects; develops new 
methodologies as needed;  (4) assists in production of, and provides graphics support for, 
presentations and manuscripts related to DPD objectives; (5) evaluates new software for 
statistical analysis, database management, graphics production, map creation, geographical 
information systems, and other functions related to DPD objectives and provides support for 
division activities in these areas.  (Approved 7/27/2004) 
Parasitic Diseases Branch (CVCHB)
(1) Investigates outbreaks and unusual occurrences of parasitic diseases when requested by state 
departments, ministries of health, the World Health Organization (WHO), and other agencies and 






diseases in the United States: (3) provides reference and laboratory diagnostic services to 
physicians and laboratories; (4) transfers technologies and expertise in laboratory diagnosis of 
parasitic infections to public health laboratories; (5) provides consultation on the treatment and 
management of parasitic diseases to clinicians, laboratorians, departments of health, and other 
agencies; (6) provides otherwise unavailable anti-parasitic drugs to healthcare providers and 
ensures compliance with the Food and Drug Administration’s regulations; (7) provides 
leadership and technical expertise in support of the agency’s bioterrerorism preparedness 
response initiatives as they relate to waterborne venues; (8) supports the agency’s overall 
emergency response mandate; (9) conducts research on methods to detect parasites and agents of  
bioterrorism in water, and developing emergency public health response plans;  (10) conducts 
field and laboratory investigations and research on the etiology, biology, epidemiology, ecology, 
pathogenesis, immunology, genetics, host-parasite relationships, chemotherapy  and other 
aspects of parasitic diseases to develop new tools for identifying and controlling parasitic 
diseases; (11) develops and tests new laboratory methods and tools for improved diagnosis, 
control, and prevention of parasitic diseases; (12) evaluates current strategies and develops new 
strategies for the control and elimination of parasitic diseases; (13) carries out and evaluates 
operational research to support programmatic activities; (14) provides technical assistance to 
ministries of health, the World Health Organization, and other agencies and organizations for 
these programs;  (15) plans, implements and evaluates such programs; (16) provides training to 
EIS officers, Emerging Infectious Disease fellows, AMS/NCID Postdoctoral Fellows, Preventive 
Medicine Residents, Public Health Prevention Specialists, and other fellows and students;  
(17) prepares educational materials on the prevention and treatment of parasitic diseases;  
(18) conducts laboratory training courses for public health laboratories; (19) prepares and 
disseminates health communication materials. (Approved 7/27/2004) 
Malaria Epidemiology Branch (CVCHC)
(1) Conducts malaria surveillance, prevention, and control in U. S. residents and visitors, 
including monitoring the frequency and distribution of malaria cases that occur in U.S. residents 
and visitors; monitoring the efficacy and safety of antimalarial drugs for chemoprophylaxis and 
chemotherapy; offering clinical advice and epidemiologic assistance on the treatment, control, 
and prevention of malaria in the United States and in malaria endemic countries; and  providing 
information to the U. S. public and to agencies or groups serving this population on appropriate 
measures to prevent and control malaria; (2) provides consultation, technical assistance, and 
training to malaria-endemic countries and to international and United States agencies and 
organizations on issues of malaria prevention and control; (3) conducts epidemiologic, 
laboratory, and field-based research projects, in support of Malaria Branch mandates (#1 and #2 
above), including laboratory and field studies on parasitic diseases to define biology, ecology, 
transmission dynamics, parasite species differences , host-parasite relationships, diagnostics, host 
immune responses, populations at risk, and determinants of morbidity and mortality;  
(4) conducts laboratory studies of malaria parasites, emphasizing animal models and in vitro 
systems for parasitic relationships, chemotherapy, and vaccine evaluation studies; (5) conducts 
field studies of malaria prevention and control tools and strategies; (6) conducts assessments of 












(1) Conducts laboratory and field research to develop, evaluates, and implements effective 
surveillance and vector arthropod control strategies; (2) develops and utilizes analytical methods 
for the use of pesticides for the control of vector-borne diseases, identification and quantification 
of anti-parasitic drugs, pharmaceutical products, and their metabolites in body fluids and tissues 
of humans and other animals; (3) serves as a WHO Collaborating Center or as an international 
standardized reference reagent and vector repository for methods development, training, 
surveillance, and research for insecticide resistance, vector identification, antimalarial drug 
evaluation, host-vector relationships, vector control; (4) provides entomological consultation and 
training to local, state, foreign and international health organizations on surveillance and control 
of vectors and vector-borne diseases; (5) conducts studies or collaborates on other disease 
surveillance and control initiatives as needed. (Approved 7/27/2004) 
 Division of Vector-Borne Infectious Diseases (CVCJ)
(1) Conducts surveillance, investigations, and studies of vector-borne viral and bacterial diseases 
and plague to define disease etiology and to develop effective methods and strategies for 
diagnosis, prevention, and control; (2) conducts investigations on the biology, ecology, and 
control of arthropod vectors of viral and bacterial diseases as a basis for development of new 
and/or modification of existing measures for more effective prevention and control; (3) conducts 
or participates in clinical, field, and laboratory studies to develop, evaluate, and improve 
laboratory methods and materials and therapeutic practices used for diagnosis, prevention, and 
treatment of vector-borne infectious diseases; (4) provides epidemic aid and epidemiologic 
consultation, upon request, to State and local health departments, other Federal agencies, and 
national and international health organizations; (5) provides reference/diagnostic services for 
vector-borne viral and bacterial diseases to State and local health departments, other Federal 
agencies, and national and international health organizations; (6) conducts research and 
collaborates on development and evaluation of immunizing agents and the role of protective 
immunity in the disease process; (7) provides guidance and scientific direction to the San Juan, 
Puerto Rico, field activities for application of effective programs in surveillance, diagnosis, 
prevention, and control of dengue fever; (8) provides scientific and technical assistance to other 
NCID components when the work requires unique expertise or specialized equipment not 
available in other components; (9) provides intramural and extramural technical expertise and 
assistance in professional training activities; (10) serves as appropriately designated national and 
international reference centers for vector-borne viral and bacterial diseases. 
Arbovirus Diseases Branch (CVCJB)
(1) Conducts surveillance, field investigations and laboratory studies of vector-borne viral agents 
and their vectors; (2) defines disease etiology, ecology, and pathogenesis in order to develop 
methods and strategies for disease diagnosis, surveillance, prevention and control; (3) provides 
diagnostic reference consultation, epidemic aid and epidemiologic consultation, upon request, to 
State and local health departments, other components of CDC, other Federal agencies, and 
national and international health organizations; (4) provides intramural and extramural technical 









   
 
 
Organization Collaborating Center for Reference and Research on Arboviruses. (Approved 
7/15/1996) 
Bacterial Zoonoses Branch (CVCJC)
(1) Develops and maintains surveillance for vector-borne bacterial zoonoses with emphasis on 
Lyme disease, plague, tularemia, and relapsing fever; (2) provides consultation, laboratory 
services, epidemiologic services, and epidemic aid to local and State health departments and to 
national and international agencies for these same diseases; (3) conducts laboratory and field 
research on vector-borne bacterial zoonoses to improve diagnosis, prevention, and control;  
(4) trains technical and professional personnel in diagnostic, reference, and research laboratory 
methods, epidemiology, disease ecology and control; (5) serves as the World Health 
Organization (WHO) Collaborating Center for Plague Reference and Research and the National 
Center for Lyme Disease Reference and Research. (Approved 7/15/1996) 
Dengue Branch (CVCJD)
(1) Develops and maintains national and international surveillance for dengue and dengue 
hemorrhagic fever; (2) provides laboratory reference and diagnostic services to local, State, 
national, and international health agencies; (3) provides epidemic aid and investigates dengue 
epidemics; (4) conducts field and laboratory research on the biology, behavior and control of 
Aedes aegypti and other mosquito vectors of dengue; (5) conducts research on and provide 
consultation and assistance to local, State, national, and international health agencies on 
improved methods for surveillance, prevention, and control of epidemic dengue; (6) provides 
training in laboratory and clinical diagnosis, and on surveillance, prevention, and control of 
dengue; (7) develops, implements, and evaluates new community-based intervention strategies 
for prevention of epidemic dengue; (8) serves as the WHO Collaborating Center for Reference 
and Research on Dengue Hemorrhagic Fever. (Approved 7/15/1996) 
Division of Viral and Rickettsial Diseases (CVCK)
(1) Conducts surveillance, investigations, and studies of viral and rickettsial diseases to define 
their etiology and epidemiology and to develop effective methods for prevention, diagnosis, 
treatment, and control; (2) conducts or participates in clinical, field, and laboratory research to 
develop, evaluate, and improve laboratory methods, materials, and therapeutic practices used for 
prevention, diagnosis, treatment, and control of viral, rickettsial, and prion diseases; (3) conducts 
research on virus transmission to develop effective prevention and control strategies and on 
vaccine effectiveness to assess prevention potential; (4) conducts laboratory, clinical, and 
epidemiologic studies of highly hazardous disease agents that require biosafety level 3 or 
biosafety level 4 security for their safe handling; (5) conducts ecological studies to develop and 
evaluate disease prevention and control measures; (6) provides epidemic aid, epidemiologic 
consultation, reference and diagnostic services, and technical assistance to state and local health 
departments, other federal agencies, and national and international health organizations;  
(7) provides scientific and technical assistance to other National Center for Infectious Diseases 
(NCID) and Centers for Disease Control and Prevention (CDC) components when the work 








(8) provides routine and specialized laboratory training in the diagnosis, isolation, and 
characterization of viral and rickettsial agents to personnel from state and local health 
departments and other national and international organizations; (9) provides training 
opportunities for Epidemic Intelligence Service officers and others in CDC sponsored programs, 
including postgraduate students, postdoctoral fellows, and other public health and laboratory 
scientists; (10) provides expert pathological support for various infectious diseases to state and 
local health departments, other NCID components, and national and international organizations; 
and (11) serves as appropriately designated national and World Health Organization 
collaborating centers for viral and rickettsial diseases. (Approved 4/4/2002) 
Office of Director (CVCK1)
(1) Directs and administers the programs and activities of the Division of Viral and Rickettsial 
Diseases (DVRD); (2) provides leadership and counsel on policy development and interpretation, 
budget formulation, and program planning, development, management, operations, and 
evaluation; (3) provides DVRD-wide administrative and programmatic services and coordinates 
or ensures coordination with the appropriate NCID or CDC staff offices; (4) provides liaison 
with other governmental agencies, international organizations, and other groups; (5) coordinates, 
in collaboration with the appropriate NCID and CDC components, international health activities 
related to the prevention and control of viral, rickettsial, and prion diseases; (6) coordinates, in 
collaboration with the appropriate CDC, PHS, and non-government components, CDC’s 
activities to monitor and improve the safety of blood and blood products in the United States and 
international settings, including development and enhancement of surveillance systems, conduct 
of epidemic investigations and risk assessment studies, and development and evaluation of 
prevention strategies; (7) serves as a liaison between CDC and other PHS agencies, the 
Department of Health and Human Services, non-governmental organizations, and professional 
groups on blood safety issues through active participation in federal advisory committees and 
technical committees; (8) conducts surveillance and epidemiologic investigations to facilitate the 
understanding and control of prion diseases, Reye syndrome, and Kawasaki syndrome; (9) serves 
as the primary disseminator of information from CDC, including clinical and disease prevention 
consultations to state and local health departments and/or federal and international agencies on 
the illnesses and syndromes caused by or related to viruses, rickettsiae, and prions;  
(10) augments the statistical and epidemiologic resources for the branches within the Division 
through provision of consultations and support for specific projects or investigations and helps 
develop, support, and coordinate statistical activities at the division level; (11) provides scientific 
and editorial review and clearance of manuscripts for publication, abstracts for presentation, 
protocols for Institutional Review Board (IRB) and human subjects review, and other scientific, 
programmatic, and informational materials; and (12) coordinates the implementation of a 
comprehensive public health communication program for the prevention and control of diseases 
caused by viruses, rickettsiae, and prions. (Approved 4/4/2002) 
Information Technology Activity (CVCK12)
(1) continuously consults with user community to ascertain information technology needs and to 
develop strategic and action plans; (2) provides technical expertise in the design, development, 









activities, develops systems to facilitate the acquisition of surveillance data electronically;  
(4) represents the division on NCID and CDC workgroups and councils and in other IRM related 
activities; (5) provides graphic support for presentation and desktop publishing; (6) provides 
intranet services, technical expertise, and support for the development and implementation of 
web services; (7) provides technical and cost related consultation to DVRD=s Office of the 
Director and Branches; (8) provides assistance to the end-user community for understanding new 
technology through information dissemination, coordination, and establishment of training; and 
(9) provides assurance that IRM regulations, policies, procedures, and standards are incorporated 
into the Division=s information technology plans and activities. (Approved 11/10/2003) 
Infectious Disease Pathology Activity (CVCK13)
(1) Serves as a scientific and technical resource to NCID by providing expertise in 
histopathology, molecular pathology, and ultrastructural analysis for detecting infectious disease 
agents and studying the interactions between microbial agents and host cells; (2) develops, 
improves, evaluates, and applies special immunohistologic, ultrastructural, and/or nucleic acid 
probe technologies for detecting microbial agents and/or expressed gene products in tissue 
specimens or tissue culture; (3) conducts basic and applied research into the pathogenesis of 
infectious diseases; (4) provides intramural and extramural technical and professional expertise 
for assistance in training in infectious disease pathology and molecular approaches to the 
identification of specific nucleic acid sequences and special antigens in tissue specimens;  
(5) provides for tracking, distribution, and testing of reference/diagnostic pathology specimens 
submitted through the data and special handling system; (6) provides histopathology, molecular 
pathology, and ultrastructure reference/diagnostic support and epidemic aid to state and local 
health departments, other federal agencies, and national and international health organizations; 
and (7) serves as the WHO Collaborating Center for Reference Pathology of Hemorrhagic 
Fevers and other Infectious Diseases. (Approved 4/4/2002) 
Influenza Branch (CVCKB)
Provides leadership and technical expertise for national and international programs aimed at 
improving the prevention and control of both epidemic and pandemic influenza.  In carrying out 
this mission, the Influenza Branch: (1) conducts global and national surveillance to identify 
novel variants with the potential to cause influenza epidemics and pandemics and monitors 
associated disease activity; (2) conducts investigations of important or unusual international and 
domestic influenza outbreaks; (3) conducts epidemiological and laboratory investigations to 
increase knowledge about influenza and to improve its prevention and control; (4) provides 
information and recommendations on the use of vaccines, antiviral agents, and other modalities 
to prevent, control, and treat influenza; (5) serves as the WHO Collaborating Center for 
Reference and Research on Influenza; (6) provides influenza reagents to World Health 
Organization Collaborating Laboratories worldwide and maintains a reference collection of 
human, swine, and avian influenza viruses and antisera; (7) performs reference antigenic 
analysis, molecular biologic analysis of influenza virus isolates, and post-vaccination human 
serologic studies for vaccine strain selection; (8) conducts studies into the evolution, structure, 
replication, immunology, and pathogenesis of influenza viruses; (9) evaluates influenza vaccine 











influenza vaccines and vaccines that might be used in the case of an influenza pandemic;  
(11) develops, evaluates, and improves new techniques and reagents for the diagnosis of
influenza in humans as well as the rapid identification of avian and swine influenza viruses that 
may cause human infections; (12) supports applied research directed toward improved influenza 
prevention and control; (13) provides support for national epidemiologic and laboratory capacity 
building; (14) initiates and conducts national and international laboratory and epidemiologic 
training courses; and (15) provides technical expertise and leadership for national and 
international pandemic planning activities. (Approved 4/4/2002) 
Respiratory and Enteric Viruses Branch (CVCKC)
(1) Provides reference/diagnostic services and conducts epidemiological studies and 
multinational surveillance for respiratory and enteric diseases; (2) monitors respiratory and 
enteric virus diseases through the National Respiratory and Enteric Virus Surveillance System, 
the National Enterovirus Surveillance System, and the Global Surveillance Program for Wild 
Polioviruses; (3) conducts clinical and epidemiologic studies and investigates outbreaks related 
to respiratory and enteric virus diseases; (4) conducts studies of the biology, biochemical and 
antigenic characteristics, and immunology and pathogenesis of respiratory and enteric viruses 
and associated disease; (5) develops, analyzes, and improves diagnostic methods and reagents 
for respiratory and enteric viruses, (6) develops and evaluates vaccines and vaccination programs 
for measles virus, rotavirus, and non-influenza respiratory viruses; (7) provides support for 
global eradication of measles virus and poliomyelitis; and (8) serves as the WHO Collaborating 
Center for Virus Reference and Research for Respiratory Virus Diseases Other Than Influenza, 
the WHO Collaborating Center for Virus Reference and Research (Enteroviruses), the WHO 
Collaborating Center for Polio, the WHO Collaborating Center for Rotavirus Investigators, and 
the WHO Collaborating Center for Measles (Approved 4/4/2002) 
Special Pathogens Branch (CVCKD)
(1) Provides epidemic aid and conducts epidemiologic studies on the detection, prevention, and 
control of highly hazardous viral diseases; (2) provides primary isolation, identification, and 
characterization of highly hazardous disease agents that require biosafety level 3 or biosafety 
level 4 laboratory conditions for their safe handling; (3) develops, evaluates, and improves 
methods for treatment, prevention, and laboratory diagnosis of hazardous disease agents;  
(4) conducts laboratory, clinical, and epidemiologic investigations on the pathogenesis, 
pathophysiology, and prevention of viral infections caused by highly hazardous viruses;  
(5) provides consultation on the clinical and epidemiologic management of suspected cases 
and/or epidemics of these diseases, including rapid development of a field laboratory;  
(6) consults with national and international scientists on the design, staffing, and efficient 
operation of a high hazard pathogen laboratory program; (7) serves as a WHO Collaborating 
Center for Virus Reference and Research for Viral Hemorrhagic Fevers; and (8) develops and 
evaluates health education programs for educating the general public and health professionals 
about infection, treatment, infection control in clinical settings, prevention, and laboratory 
diagnosis of highly hazardous viral diseases. (Approved 4/4/2002) 











(1) Conducts surveillance and laboratory-based epidemiologic studies of chronic fatigue 
syndrome (CFS); (2) serves as the WHO Collaborating Center for Smallpox and Other Poxvirus 
Infections and provides reference/diagnostic services for suspected smallpox and other poxvirus 
infections, with emphasis on bioterrorism; (3) serves as the Varicella Zoster Virus National 
Laboratory; (4) conducts laboratory-based epidemiologic studies of human papillomavirus 
(HPV) infection and diseases with emphasis on control/prevention of cervical cancer and 
recurrent respiratory papillomatosis; (5) conducts laboratory-based epidemiologic studies of 
herpesviruses, with emphasis on infections in immunocompromised hosts, congenital and 
perinatal infections, and disease; (6) conducts research concerning human immune responses to 
herpes, HPV, and poxviruses; (7) develops, evaluates, and improves methods and reagents for 
rapid diagnosis of viral infections; (8) provides epidemiology, molecular biology, diagnostic 
serology/virology, and immunology consultation and collaboration to national and international 
organizations concerning prevention and control of CFS, poxvirus, HPV, and herpesvirus 
diseases, virus-associated cancers, and vaccine programs; and (9) provides assistance regarding 
DNA virus infection and associations between viruses, host genetics, host immune response, and 
human disease as necessary. (Approved 4/4/2002) 
Viral and Rickettsial Zoonoses Branch (CVCKG)
(1) Provides epidemic aid, consultation, surveillance, and epidemiologic and ecologic 
investigations of viral, rickettsial, and bartonella-associated zoonoses domestically and 
internationally; (2) conducts studies on the microbiology, molecular biology,  pathogenesis, and 
pathology of viral, rickettsial, and bartonella-associated zoonotic infections: (3) provides 
reference/diagnostic services domestically and internationally; (4) develops, evaluates, and 
improves methods and reagents for diagnosing viral, rickettsial, and bartonella-associated 
diseases; (5) develops and evaluates human and animal vaccines and other prophylactic agents 
for zoonotic diseases and prepares recommendations for their use; (6) serves as a WHO 
Collaborating Center for Reference and Research on Rabies and a WHO Collaborating Center 
for Rickettsial and Bartonella-associated Reference and Research; (7) provides consultation and 
laboratory training to state and local health departments and other national and international 
organizations; (8) responds to requests for information regarding viral, rickettsial, and bartonella-
associated zoonotic diseases and their prevention from CDC, health care providers, academic 
institutions, state and local health departments, other government agencies, and the general 
public; (9) collaborates with government agencies, domestic and international academic 
institutions, and the private sector in developing novel diagnostic assays and vaccines for viral, 
rickettsial, and bartonella-associated zoonotic diseases; and (10) maintains the Bioterrorism
Laboratory for Coxiella burnetii (Q fever) and rickettsial response and research.  (Approved 
4/4/2002) 
Division of Viral Hepatitis (CVCL)
(1) Conducts surveillance and special studies to determine the epidemiology and disease burden 
associated with acute and chronic infections and liver disease associated with hepatitis viruses; 
(2) conducts epidemiologic and laboratory studies, including outbreak investigations, to 






history and pathogenesis of these infections, and determine their health impact; (3) conducts 
epidemiologic, clinical, laboratory, behavioral, and health communications research to develop 
and evaluate methods and strategies for the prevention of infections with hepatitis viruses and 
their acute and chronic disease consequences; (4) develops, implements, communicates, and 
evaluates recommendations and standards for the prevention and control of infections and liver 
disease associated with hepatitis viruses; (5) provides technical and programmatic leadership and
assistance to state and local health departments, non-governmental organizations, and the 
international community to develop, implement, and evaluate programs to prevent infections 
with hepatitis viruses and their consequences, including immunization to prevent hepatitis A and 
eliminate transmission of hepatitis B virus infection, counseling and testing to prevent and 
control hepatitis C virus infection, and improvement of transfusion and medical practices and 
reduced frequency of unsafe injections to prevent transmission of bloodborne virus infections, 
including hepatitis viruses; (6) provides leadership and coordination to integrate viral hepatitis 
prevention and control activities into other prevention programs conducted by CDC, other 
Federal agencies, and health care providers; (7) conducts laboratory, clinical, and epidemiologic 
studies to develop and evaluate methods for the diagnosis of infections with hepatitis viruses;  
(8) identifies and characterizes agents and host factors associated with hepatitis and acute and 
chronic liver disease; (9) provides epidemic aid, epidemiologic and laboratory consultation, 
reference diagnostic services, and technical assistance to state and local health departments, other 
federal agencies, other components of CDC, and national and international health organizations; 
(10) disseminates information through health communications materials, tools and programs, 
scientific publications, and presentations; (11) provides training opportunities for Epidemic 
Intelligence Service Officers and others in CDC sponsored programs, including postgraduate 
students, post-doctoral fellows, and other public health and laboratory scientists; and (12) serves 
as a WHO Collaborating Center for Reference and Research on Viral Hepatitis. (Approved 
4/4/2002) 
Office of the Director (CVCL1)
(1) Directs, administers, and provides oversight for the programs and activities of DVH, 
including budget formulation and administration; (2) provides leadership and counsel on policy 
development and interpretation and on program planning, development, management, and 
evaluation; (3) provides Division-wide administrative and program support services and 
coordinates and ensures coordination with the appropriate National Center for Infectious 
Diseases (NCID) and Centers for Disease Control and Prevention (CDC) staff offices;  
(4) provides the leadership and coordination, including serving on appropriate advisory 
committees, to integrate viral hepatitis and liver disease prevention and control activities into 
other prevention programs conducted by NCID, CDC, Department of Health and Human 
Services, other Federal agencies, international organizations, and other groups; (5) provides 
leadership and oversight to the provision of state-or-the-art informatics for DVH, including 
information systems, computer programs, programming and data management support, and 
management of DVH internet and intranet websites; (6) provides manuscript review and 
clearance and coordination and oversight for studies, human subjects review, OMB clearance, 
Freedom of Information Act (FOIA) requests, other controlled correspondence, and requests for 
information;(7) coordinates and provides oversight for continuing professional education 









graphics and other visual arts, and conference and exhibit planning, management, and execution. 
(Approved 7/21/2006) 
Epidemiology Branch (CVCLB)
(1) Monitors and evaluates rates and risk factors associated with acute and chronic infections 
with hepatitis viruses, viral hepatitis and liver disease through surveillance systems and special 
studies, including sentinel surveillance; (2) conducts research, including outbreak investigations, 
clinical trials and population-based demonstration projects, to determine the epidemiology of 
transmission of known and new hepatitis viruses and their variants, the natural history of 
infections with hepatitis viruses, evaluate the performance of diagnostic tests for hepatitis virus 
infections, and evaluate methods and approaches for the prevention and control of hepatitis virus 
infections; (3)  estimates disease burden attributable to infections with hepatitis viruses and the 
effectiveness of programs to prevent these infections; (4) provides consultation to state, local, 
national, and international authorities for the prevention and control of viral hepatitis, the 
investigation of disease outbreaks, and surveillance of hepatitis and liver disease;
(5) disseminates information through scientific publications and presentations; and (6) provides 
training opportunities for Epidemic Intelligence Service Officers and others in CDC sponsored 
programs, postgraduate students, post-doctoral fellows, and other public health scientists. 
(Approved 4/4/2002) 
Prevention Branch (CVCLC)
(1) Develops, administers, implements, and evaluates domestic and international programs to 
prevent viral hepatitis, including those that serve clients in the public and private sectors, through 
state and local health departments, health organizations, academic institutions, and non-
governmental organizations; (2) provides leadership and coordination for viral hepatitis and liver 
disease prevention and control programs with other components of CDC, other Federal agencies, 
and non-governmental agencies and partners; (3) conducts research to ascertain educational and 
communication needs, best methods of communication, and effectiveness of educational 
programs for health professionals, the public, and persons in groups at risk for infection with 
hepatitis viruses and develops and disseminates accurate, timely and effective educational 
materials, tools, and programs related to the prevention of viral hepatitis and liver disease;  
(4) develops and implements accurate, timely, and effective educational tools, materials and 
programs for prevention of viral hepatitis and liver disease; (5) develops and conducts studies, 
including economic and behavioral studies, to evaluate the effectiveness of interventions and 
programs to prevent viral hepatitis and to identify barriers to prevention services such as 
immunization, counseling, testing, medical referral, and management; (6) develops and evaluates 
health services models for prevention of infection with hepatitis viruses and associated liver 
disease; (7) provides leadership and coordinates the development of national standards and 
performance objectives for prevention of viral hepatitis and liver disease and works with 
agencies and partners to adopt these standards; (8) develops indicators and measures by which to 
evaluate the performance and effectiveness of  viral hepatitis prevention programs;  
(9) disseminates information through scientific publications and presentations; and (10) provides 
training opportunities for Epidemic Intelligence Service Officers and others in CDC sponsored 










(1) Conducts research and applies state-of-the-art laboratory methods in support of studies 
related to the epidemiology, molecular epidemiology, and natural history of acute and chronic 
infections with hepatitis viruses and liver disease; (2) conducts research to develop and validate 
diagnostic approaches to identify infections with hepatitis viruses; (3) develops and evaluates 
methods to prevent acute and chronic infection and disease outcomes, including vaccines;  
(4) determines the viral, immunologic, and other host responses to infection with hepatitis 
viruses in humans and animal models; (5) identifies and characterizes agents that cause hepatitis; 
(6) provides reference diagnostic testing for markers of infection with hepatitis viruses for state 
and local public health laboratories; (7) provides the leadership and collaboration to ensure the 
transfer to public health laboratories, both nationally and internationally, state-of-the-art methods 
and approaches for the identification and diagnosis of infections with hepatitis viruses;  
(8) develops and maintains archives of clinical specimens from clinical trials and epidemiologic 
and laboratory studies; (9) disseminates information through scientific publications and 
presentations; and (10) provides training opportunities for persons in CDC sponsored programs, 
postgraduate students, post-doctoral fellows, and other public health scientists. (Approved 
4/4/2002) 
